ARTICLE SUMMARY:
Automated insulin delivery systems were a highlight of this year’s (virtual) ADA meeting, with presentations on new devices from Medtronic, Tandem Diabetes Care, Insulet, Beta Bionics, and Eli Lilly, all vying for a top spot in this fast-evolving space. Industry analysts opine on their commercial prospects as well as Dexcom and Abbott’s efforts to expand CGM to the type 2 diabetes population.
The 2020 American Diabetes Association (ADA) meeting was held remotely in mid-June and thus was more subdued than in previous years; however, some important device studies were presented, particularly in the areas of next-gen automated insulin delivery (AID) systems and continuous glucose monitoring (CGM).